Management Credibility Analysis

Unavailable
Verified Management Score Unavailable
Management credibility requires sourced guidance and earnings history.

Upcoming Catalysts

Verified event feed
Verified Catalysts Unavailable
No sourced upcoming event feed is configured for this stock yet.

Company profile

No description available

Chief executive
Not disclosed
Headquarters
3911 SORRENTO VALLEY BLVD, SAN DIEGO, CA
Founded
Not disclosed

📈 Company Timeline

Major business events
Positive
Negative
Neutral
24 Sep 2026

Ligand Pharmaceuticals Incorporated reported Regulation FD disclosure

Ligand Pharmaceuticals Incorporated filed an 8-K covering Regulation FD disclosure, another company event.

22 Sep 2026

Ligand Pharmaceuticals Incorporated reported Regulation FD disclosure

Ligand Pharmaceuticals Incorporated filed an 8-K covering Regulation FD disclosure, supporting financial statements or exhibits.

13 Aug 2026

Large-holder ownership filing

A holder reported or amended a beneficial ownership position of more than 5% in Ligand Pharmaceuticals Incorporated.

8 Aug 2026

Ligand Pharmaceuticals Incorporated filed Form 10-Q

Ligand Pharmaceuticals Incorporated submitted Form 10-Q to the SEC for the period ending Jun 30, 2026.

6 Aug 2026

Ligand Pharmaceuticals Incorporated reported Operating or financial results

Ligand Pharmaceuticals Incorporated filed an 8-K covering operating or financial results, supporting financial statements or exhibits.

Capital Structure & Financial Position

Financial strength and liquidity analysis
Cash and equivalents (USD)$1.01B
Total assets (USD)$2.19B
Total liabilities (USD)$1.22B
Shareholders' equity (USD)$967.52M
Long-term debt (USD)$1.13B

Source: SEC EDGAR company facts (opens in a new tab) Balance sheet dated

Peer Comparison - Health Care

Company Price Market Cap
LLY - Eli Lilly and Company $1,276.13
Yahoo Finance 		$1.20T
JNJ - Johnson & Johnson $256.74
Yahoo Finance 		$618.71B
ABBV - AbbVie Inc. $284.80
Yahoo Finance 		$503.28B
UNH - UnitedHealth Group Incorporated $418.43
Yahoo Finance 		$375.58B
MRK - Merck & Co., Inc. $148.55
Yahoo Finance 		$366.50B

📋 Corporate Actions

Recent and upcoming corporate events
Verified Corporate Actions Unavailable
Dividend, buyback, split, and spin-off feeds are not ingested for this stock yet.

Financials

Financial statements and key metrics analysis
QuarterRevenue (USD)Operating incomeNet incomeDiluted EPS (USD)Filed
Q2 2026$63.69M$8.59M$48.51M$2.2210-Q · 7 Aug 2026
Q1 2026$51.72M$17.37M−$13.35M−$0.6710-Q · 8 May 2026
Q4 2025$59.67M$13.84M$44.78MUnavailable10-K · 27 Feb 2026
Q3 2025$115.46M$54.93M$117.27M$5.6810-Q · 7 Nov 2025
Q2 2025$47.63M$8.44M$4.85M$0.2410-Q · 8 Aug 2025
Q1 2025$45.33M−$36.22M−$42.45M−$2.2110-Q · 9 May 2025

Source: SEC EDGAR company facts (opens in a new tab)

Analyst Consensus

Buy
Target: $362.83
17.0% upside potential
📈
Strong Buy
Unavailable
👍
Buy
8
⏸️
Hold
0
📉
Sell
0
8 analysts covering this stock

Source: Nasdaq analyst research (opens in a new tab) Retrieved Targets range 326.00–406.00 Ratings are third-party opinions, not advice.

💰 Upcoming Dividends

Next dividend payments
Verified Dividend Data Unavailable
Dividend calendar data is not ingested for this stock yet.

Guidance Evolution

Verified Guidance History Unavailable
Verified company guidance history is not ingested for this stock yet.

💼 Director Transactions

Recent insider activity
2
Oct 2026
Reardon Andrew
CLO & Secretary
Option exercise
$52.27 per share
340 shares
SEC Form 4
2
Oct 2026
Reardon Andrew
CLO & Secretary
Open-market sale
$304.07 per share
5,000 shares
SEC Form 4
22
Sep 2026
Zimmermann Martine
Director
Tax withholding
$298.50 per share
115 shares
SEC Form 4
10
Sep 2026
Zimmermann Martine
Director
Open-market sale
$285.00 per share
1,200 shares
SEC Form 4
3
Sep 2026
Reardon Andrew
CLO & Secretary
Open-market sale
$286.09 per share
5,000 shares
SEC Form 4
12
Aug 2026
Espinoza Octavio
Chief Financial Officer
Option exercise
$56.91 per share
31,641 shares
SEC Form 4
12
Aug 2026
Espinoza Octavio
Chief Financial Officer
Open-market sale
$292.07 per share
31,641 shares
SEC Form 4
12
Aug 2026
Haas Jason
Director
Option exercise
$51.56 per share
6,138 shares
SEC Form 4
12
Aug 2026
Haas Jason
Director
Open-market sale
$292.81 per share
7,138 shares
SEC Form 4
3
Aug 2026
Reardon Andrew
CLO & Secretary
Option exercise
$52.27 per share
5,000 shares
SEC Form 4

Top Shareholders

Blackrock, Inc.
3,100,996 shares
4.695% change
6/30/2026
Vanguard Group Inc
2,073,892 shares
-0.115% change
12/31/2025
Invesco Ltd.
1,201,644 shares
45.901% change
6/30/2026
Vanguard Portfolio Management Llc
1,138,316 shares
3.458% change
6/30/2026
Jupiter Topco Llc
1,040,578 shares
New% change
6/30/2026
Janus Henderson Group Ltd.
1,009,891 shares
1.456% change
3/31/2026
Vanguard Capital Management Llc
870,950 shares
2.696% change
6/30/2026
State Street Corp
826,539 shares
6.122% change
6/30/2026
Fmr Llc
762,827 shares
27.964% change
6/30/2026
Franklin Templeton Inc
752,044 shares
31.206% change
6/30/2026

Source: Nasdaq institutional holdings (opens in a new tab) Observed · 13 hours ago